Related Experiment Videos
[Effect of Trusopt on normal intraocular pressure values in children]
J Rehůrek1, R Spicarová, J Vancurová
1Klinika dĕtské oftalmologie LF MU a FN, Brno.
Insights
Dorzolamide (TRUSOPT) significantly lowered intraocular pressure in children aged 4-15. This safe, single-dose treatment offers a potential new approach for pediatric glaucoma management.
Area of Science:
- Ophthalmology
- Pharmacology
Context:
- Intraocular pressure (IOP) management in pediatric populations is critical.
- Limited pharmacological options exist for treating elevated IOP in children.
- Childhood glaucoma requires effective and safe treatment strategies.
Purpose:
- To evaluate the efficacy and safety of topical dorzolamide (TRUSOPT) in reducing intraocular pressure in healthy children.
- To assess the impact of a single dose of dorzolamide on natural IOP in a pediatric cohort.
- To investigate the potential of TRUSOPT as a treatment for pediatric glaucoma.
Summary:
- A study involving 406 healthy children (ages 4-15) administered a single dose of dorzolamide (TRUSOPT).
- Intraocular pressure was measured using a non-contact tonometer (NIDEK NT 1100).
- A statistically significant reduction in IOP was observed, from an average of 16.08 mm Hg to 14.07 mm Hg, with no adverse effects reported.
Impact:
- This study provides the first statistically significant evidence of dorzolamide's effect on IOP in healthy children.
- The findings suggest dorzolamide (TRUSOPT) may be a viable and safe pharmacological option for managing pediatric glaucoma.
- Highlights a potential underutilized treatment for childhood glaucoma.
Abstract:
The authors investigated a group of 406 healthy eyes of children aged 4 to 15 years to test the effect of the local carboanhydrase inhibitor TRUSOPT on natural previously assessed intraocular pressure. The measurements made by means of an air-puff contact-free tonometer NT 1100 NIDEK revealed a highly significant decline of intraocular pressure--from 16.08 mm Hg to 14.07 mm Hg on average in the whole group. The tolerance of the drug after a single administration caused no problems, no undesirable effect was recorded. This is the first and only report on the effect of TRUSOPT on normal intraocular pressure of the child eye reported in the literature in a statistically significant group. The authors are surprised by the fact that the possibility of favourable pharmacological treatment of child glaucoma with clinically widely used Trusopt is not used so far.